Identification of Coronary Thrombus With a IIb/IIIa Platelet Inhibitor Radiopharmaceutical, Technetium-99m DMP-444

Mitchel, Joseph F.; Waters, David D.; Lai, Tianjie; White, Michael P.; Alberghini, Tod V.; Salloum, Ahmad; Knibbs, David R.; Li, Dadong; Heller, Gary V.

doi:10.1161/01.cir.101.14.1643

Cited by 33 publications

(20 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, other plaque-associated targets have been used as biomarkers for nuclear imaging. 31,32 We believe that the enzyme-sensitive beacons could have advantages as imaging agents because of their inherent built-in amplification and because they report molecular rather than anatomic abnormalities.…”

Section: Discussionmentioning

confidence: 99%

In Vivo Imaging of Proteolytic Activity in Atherosclerosis

et al. 2002

View full text Add to dashboard Cite

Background-Atherosclerotic plaque rupture, the most important cause of acute cardiovascular incidents, has been strongly associated with vascular inflammation. On the basis of the hypothesis that the inflammatory response and proteolysis lead to plaque rupture, we have examined the role of cathepsin B as a model proteolytic enzyme. Methods and Results-Using western-type diet-fed apoE and apoE/endothelial NO synthase double knockout mice as models of atherosclerosis, we show (1) that cathepsin B is upregulated in atherosclerotic lesions characterized by high degrees of inflammation compared with normal aorta or silent lesions, (2) that intravenously injectable novel cathepsin B imaging beacons are highly activated within active atherosclerotic lesions and colocalize with cathepsin B immunoreactivity, and (3) that cathepsin B activity in atherosclerotic lesions can be imaged in whole animals by using a novel near-infrared tomographic imaging system. Conclusions-These studies indicate that cathepsin B, and potentially other proteases, may serve as a biomarker for vulnerable plaques when probed with beacons. The tomographic in vivo imaging method as well as catheter-based optical sensing methods could be readily adapted to screening and potentially to the molecular profiling of a number of proteases in vulnerable plaque in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vivo Imaging of Proteolytic Activity in Atherosclerosis

et al. 2002

View full text Add to dashboard Cite

show abstract

“…75 A new glycoprotein IIb/IIIa platelet inhibitor, DMP-44, labeled with 99m Tc accurately identifies the platelet-rich thrombus in a canine model. 76 We recently illustrated that in vivo fluorodeoxyglucose positron emission tomography may detect and quantify macrophage content in rabbits with aortic plaques. 77 However, no single radiotracer is ideally suited to image atherosclerosis and to provide the prognostic and clinical indicators necessary for medical and surgical interventions.…”

Section: Nuclear Scintigraphymentioning

confidence: 99%

Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque

Fayad

Fuster

2001

Circulation Research

458

293

View full text Add to dashboard Cite

Abstract-The study of atherosclerotic disease during its natural history and after therapeutic intervention will enhance our understanding of disease progression and regression and aid in selecting appropriate treatments. Several invasive and noninvasive imaging techniques are available to assess atherosclerotic vessels. Most of the standard techniques identify luminal diameter, stenosis, wall thickness, and plaque volume; however, none can characterize plaque composition and therefore identify the high-risk plaques. We will present the different imaging modalities that have been used for the direct assessment of the carotid, aortic, and coronary atherosclerotic plaques. We will review in detail the use of high-resolution, multicontrast magnetic resonance for the noninvasive imaging of vulnerable plaques and the characterization of plaques in terms of their various components (ie, lipid, fibrous, calcium, or thrombus

show abstract

“…Using the SnCl 2 -containing formulation, RP444 can be readily prepared in high yield (85-92%), and excellent images in the canine deep vein thrombosis (DVT) and arteriovenous shunt models are produced. Injection of the whole or part of the formulation did not cause any unwanted side effects [59][60][61][62].…”

Section: Sncl 2 -Containing Formulationmentioning

confidence: 99%